Pharmacological inhibitors of PARP provide significant therapeutic benefits in various preclinical disease models associated with tissue injury and inflammation. However, our understanding the role of PARP activation in the pathophysiology of liver inflammation and fibrosis is limited. In this study we ...
There is emerging data regarding the benefits of both ubiquinol and d-ribose in the management of HF [[16], [17], [18], [19]]. These substances may have beneficial properties impacting improvement in mitochondrial function. Due to the challenges in the management of HFpEF and the limited ...